SPARC investigational drug shows promise in phase 3 trial for treating inflammation, pain related to ocular surgery

Written by Ruchika Sharma Published On 2020-10-15T12:30:42+05:30 | Updated On 15 Oct 2020 12:57 PM IST

The objective of the trial was to assess the efficacy and safety of SDN-037 in clearing the inflammation and pain, the company added.

New Delhi: Sun Pharma Advanced Research Company (SPARC) on Wednesday said it has received positive top-line results from phase 3 trial for its investigational drug, SDN-037, for the treatment of inflammation and pain associated with ocular surgery. SPARC said its investigational drug met pre-specified primary and secondary endpoints.

"SPARC reported positive top-line results from its phase 3 trial for its investigational drug, SDN-037, for the treatment of inflammation and pain associated with ocular surgery. The trial met its pre-specified primary and secondary objectives," the company said in a regulatory filing.

Read also: SPARC, Sun Pharma enter into license agreement for SCD-044, a potential treatment for atopic dermatitis, psoriasis, more

The objective of the trial was to assess the efficacy and safety of SDN-037 in clearing the inflammation and pain, the company added.

Shares of SPARC were trading 0.56 per cent higher at Rs 170.30 apiece on BSE.

Read also: SPARC, Tripoint ink licensing pact for Elepsia XR tablets in US

sparcsun pharmasdn-037ocular surgerysun pharma advanced research companyinflammation

Source : PTI

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751